Maysaloun Merhi Afsheen Raza Varghese Philipose Inchakalody Abdulqadir Jeprel Japer Nashwan Niloofar Allahverdi Roopesh Krishnankutty Shahab Uddin Abdul Rehman Zar Gul Mohammed Ussama Al Homsi Said Dermime
10.3389/fimmu.2018.01769
Front Immunol
2018 Jul 30;9:1769.
ny-eso-1 antibody ny-eso-1-specific t cells cytokine profile head and neck squamous cell carcinoma nivolumab programmed cell death protein-1
CC BY
https://pubmed.ncbi.nlm.nih.gov/30108590/
Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Squamous Cell / drug therapy Carcinoma, Squamous Cell / immunology Gene Expression Regulation, Neoplastic / drug effects Head and Neck Neoplasms / drug therapy Head and Neck Neoplasms / immunology Programmed Cell Death 1 Receptor / antagonists & inhibitors
Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Squamous Cell / drug therapy Carcinoma, Squamous Cell / immunology Gene Expression Regulation, Neoplastic / drug effects Head and Neck Neoplasms / drug therapy Head and Neck Neoplasms / immunology Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Aged Antineoplastic Agents, Immunological / pharmacology Biomarkers, Tumor Carcinoma, Squamous Cell / diagnosis Carcinoma, Squamous Cell / metabolism Cytokines / blood Head and Neck Neoplasms / diagnosis Head and Neck Neoplasms / metabolism Humans Immunomodulation / drug effects Male Nivolumab / pharmacology Nivolumab / therapeutic use Positron Emission Tomography Computed Tomography Programmed Cell Death 1 Receptor / genetics Tomography, X-Ray Computed Treatment Outcome Antineoplastic Agents, Immunological Biomarkers, Tumor Cytokines Programmed Cell Death 1 Receptor Nivolumab
PMC6079623
30108590
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
2018